Amphastar Pharmaceuticals (AMPH) Share-based Compensation (2013 - 2026)

Amphastar Pharmaceuticals has reported Share-based Compensation for 14 years, with the latest figure at $29.3 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 12.69% year-over-year to $29.3 million in Q2 2026; TTM through Jun 2026 was $29.3 million, a 12.69% increase from a year earlier, with the FY2025 full-year figure at $27.3 million, up 11.94% from the prior year.
• Share-based Compensation was $29.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $9.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $29.3 million in Q2 2026, with the low at $4.3 million in Q4 2022.
• Average Share-based Compensation over 5 years is $10.4 million, with a median of $8.0 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation fell 14.23% in 2024, then jumped 272.17% in 2025.
• Over 5 years, Share-based Compensation stood at $4.3 million in 2022, then climbed by 7.39% to $4.6 million in 2023, then climbed by 21.85% to $5.6 million in 2024, then advanced by 10.17% to $6.2 million in 2025, then surged by 372.2% to $29.3 million in 2026.
• The last three Share-based Compensation figures came in at $29.3 million (Q2 2026), $9.3 million (Q1 2026), and $6.2 million (Q4 2025), per Business Quant data.